New drug delivery options for migraine

Expert Review of Neurotherapeutics

Volumn 11, Issue 6, 2011, Pages 771-773

  Vikelis, Michail ^a   Rapoport, Alan M ^b,c  

^a Glyfada Headache Center   (Greece)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NEW ENGLAND CENTER FOR HEADACHE   (United States)

Author keywords

dihydroergotamine oral inhalation; intranasal sumatriptan; Levadex ; migraine; OptiNose ; transdermal sumatriptan; Zelrix

Indexed keywords

DIHYDROERGOTAMINE; ERGOTAMINE TARTRATE; PLACEBO; SUMATRIPTAN;

ANALGESIA; APPLICATION SITE REACTION; AREA UNDER THE CURVE; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ELECTRIC CURRENT; ELECTROCARDIOGRAM; FIRST PASS EFFECT; HUMAN; INHALER; IONTOPHORESIS; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MULTICENTER STUDY (TOPIC); NAUSEA; NAUSEA AND VOMITING; NOSE AIRFLOW; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; PHONOPHOBIA; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SPIROMETRY; TASTE DISORDER; THORAX PAIN; VITAL SIGN;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ANALGESICS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; MIGRAINE DISORDERS;

EID: 79958283301     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.62     Document Type: Review

References (15)

1. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 35(7), 387-396 (1995).
2. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine II Study. Headache 41(7), 646-657 (2001). (Pubitemid 32777747)
3. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey. Headache 43(1), 19-26 (2003). (Pubitemid 36150986)
4. Monteith TS, Goadsby PJ. Acute migraine therapy: new drugs and new approaches. Curr. Treat. Options Neurol. 13(1), 1-14 (2011).
5. Luthringer R, Djupesland PG, Sheldrake CD, et al. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J. Pharm. Pharmacol. 61(9), 1219-1228 (2009).
6. Djupesland PG, Docekal P; Czech Migraine Investigators Group. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomized, placebo-controlled study. Cephalalgia 30(8), 933-942 (2010).
7. Djupesland PG, Skretting A, Windern M, et al. Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngoscope 116(3), 466-472 (2006). (Pubitemid 44318113)
8. Siegel SJ, O'Neill C, Dube LM, et al. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan succinate. Headache 47(5), 753 (2007).
9. Pierce M, Marbury T, O'Neill C, et al. Zelrix: a novel transdermal formulation of sumatriptan. Headache 49(6), 817-825 (2009).
10. Goldstein J, Pugach N, Smith TR. Acute anti-migraine efficacy and tolerability of Zelrix, a novel iontophoretic transdermal patch of sumatriptan. Cephalalgia 29(Suppl. 1), 20 (2009).
11. Pierce MW. Transdermal delivery of sumatriptan for the treatment of acute migraine. Neurotherapeutics 7(2), 159-163 (2010).
12. Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Neurology 45(3 Pt 1), 577-584 (1995).
13. Shrewsbury SB, Cook RO, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler. Headache 48(3), 355-367 (2008). (Pubitemid 351517766)
14. Aurora SK, Rozen TD, Kori SH, et al. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 49(6), 826-837 (2009).
15. Silberstein SD, Kori SH, Tepper SJ, et al. Efficacy and tolerability of MAP0004, a novel orally inhaled therapy, in treating acute migraine. Cephalalgia 1(Suppl. 1), 12 (2009).